OncoLink Cancer Treatment and Resources

Percentage of Free PSA in Black versus White Men for Detection and Staging of Prostate Cancer: A Prospective Multicenter Clinical Trial

William J. Catalona, Alan W. Partin, Kevin M. Slawin, et al.
Abramson Cancer Center of the University of Pennsylvania
Last Modified: November 1, 2001

Reviewers: Li Liu, MD
Source: Urology, Volume 55:372-376, (March) 2000.

Précis: Free PSA percentage is effective for prostate cancer detection in black men.

Introduction

Measurement of serum prostate-specific antigen (PSA) is widely used as an aid in the early detection of prostate cancer. Prostate-specific antigen exists in multiple forms in serum, both bound and free. For unknown reasons, the percentage of free PSA is lower in serum samples from patients with prostate cancer than in serum samples from patients with a normal prostate or benign disease. Low percentages of free PSA are well established as indicators of prostate cancer, but the difference between races has not been evaluated.

Method

In this study, a total of 79 black and 647 white men were screened for prostate cancer. All subjects were between the ages of 50 and 75 years, with PSA concentrations between 4.0 and 10.0 ng/ml and nonsuspicious digital rectal examination findings. All men had undergone needle biopsy of the prostate.

Results

  • A lower percentage free PSA indicated a higher probability of prostate cancer and a higher percentage free PSA indicates a low probability of cancer for both races.
  • At a free PSA cutoff of 25%, the sensitivity was 95% in both blacks and whites.

Discussion

In this study, determination of the percentage of free PSA has the same sensitivity and specificity in detecting early prostate cancer in black men as in white men with the use of 25% free PSA as cutoff, unnecessary biopsies could have been avoided in approximately 25% of both white and black men. This result may not apply to men with PSA of < 4.0 or > 10.0 ng/ml.

OncoLink I wish u knew...

Dr. Giantonio discusses the importance of oncology clinical trials and clarifies some myths about studies. Read more.

Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet

Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy

Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies

Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer

Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults

OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews


Ask the Experts
Brown Bag Chat
Tracy's Corner

About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement

OncoLink Cancer Resources RSS What's New RSS